Lupus-like symptoms with anti-RNP/Sm and anti-nuclear antibodies positivity: An extremely rare adverse event of dasatinib

Abstract

Introduction

Dasatinib is a potent tyrosine-kinase inhibitor which is used for chronic myeloid leukemia treatment. Pleural effusion is a frequent side effect in patients during dasatinib treatment. Pulmonary arterial hypertension is a rare and life-threatening adverse event of dasatinib. The relationship between dasatinib and autoimmune disorders is unclear, but there are reports of possible mechanisms that have triggered autoimmunity by dasatinib.

Case report

A 53-year-old male was diagnosed with chronic myeloid leukemia and initiated imatinib mesylate as a treatment. Imatinib was changed to dasatinib as the patient was unresponsive in the first year of treatment. In the fourth year of dasatinib when chronic myeloid leukemia was in both hematological and cytogenetical remission, the patient presented with bilateral massive exudative pleural effusion. Echocardiography was consistent with pericardial effusion with right ventricle enlargement and normal left-side cardiac function. Pulmonary arterial hypertension was diagnosed with high systolic pulmonary arterial pressure. When he had fever and arthralgia, further investigation showed positivity of anti-nuclear antibodies (1/160 titer) and anti-RNP/Sm, which have high specificity for the diagnosis of Systemic Lupus Erythematosus (SLE).

Management and outcome

Dasatinib was discontinued and nilotinib was initiated. As the pleural effusion persisted despite diuretics and methylprednisolone, mycophenolate mofetil was initiated as a steroid-sparing immune-suppressive agent. The lupus-like symptoms disappeared, and antibodies became undetectable after dasatinib discontinuation. Pericardial effusion improved and pleural effusion did not relapse.

Discussion

Screening for auto-antibodies may be recommended for patients with a history or symptoms of autoimmune disease before starting dasatinib. All patients who develop pleural effusion while on dasatinib treatment should be investigated for antibodies for lupus.

Keywords

Dasatinib lupus pleural effusion pulmonary arterial hypertension

Get full access to this article

View all access options for this article.

References

Kreutzman

Ilander

Porkka

, et al. Dasatinib promotes Th1-type responses in granzyme B expressing T-cells. Oncoimmunology 2014; 3: 28925–28925.

Wang

, et al. Dasatinib promotes the potential of proliferation and antitumor responses of human gamma-delta T cells in a long-term induction ex vivo environment. Leukemia 2014; 28: 206–210.

Mustjoki

Auvinen

Kreutzman

, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia 2013; 27: 914–924.

Mustjoki

Ekblom

Arstila

, et al. Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy. Leukemia 2009; 23: 1398–1405.

Rohon

Porkka

Mustjoki

. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol 2010; 85: 387–398.

Kreutzman

Juvonen

Kairisto

, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood 2010; 116: 772–782.

Cortes

Saglio

Kantarjian

, et al. Final 5-year study results of DASISION: the dasatinib versus imatinib study in treatment-naïve chronic myeloid leukemia patients trial. J Clin Oncol 2016; 34: 2333–2340.

Nagata

Ohashi

Fukuda

, et al. Clinical features of dasatinib-induced large granular lymphocytosis and pleural effusion. Int J Hematol 2010; 91: 799–807.

Quintas-Cardama

Kantarjian

O’Brien

, et al. Pleural effusion in patients with chronic myelogenous leukemia treated with dasatinib after imatinib failure. J Clin Oncol 2007; 25: 3908–3914.

10.

Tacoy

Cengel

Ozkurt

, et al. Dasatinib-induced pulmonary hypertension in acute lymphoblastic leukemia: case report. Turk Kardiyol Dern Ars 2015; 43: 78–81.

11.

Guignabert C, Phan C, Seferian A, et al. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension. Clin Invest 2016: 126; 3207–18.

12.

Nagaraj

Tang

Balint

, et al. SRC tyrosine kinase is crucial for potassium channel function in human pulmonary arteries. Eur Respir J 2013; 41: 85–95.

13.

Weatherald

Chaumais

M-C

Savale

, et al. Long-term outcomes of dasatinibinduced pulmonary arterial hypertension: a population-based study. Eur Respir J 2017; 50: 1700217–1700217.

14.

Naranjo

Busto

Sellers

, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

15.

Borchers

Keen

Gershwin

. Drug-induced lupus. Ann N Y Acad Sci 2007; 1108: 166–182.

16.

Crispin

Kyttaris

Juang

Y-T

, et al. How signalling and gene transcription aberrations dictate the systemic lupus erythematosus T cell phenotype. Trends Immunol 2008; 29: 110–115.

17.

Rea

Bergeron

Fieschi

, et al. Dasatinib-induced lupus. Lancet 2008; 372: 713–714.

18.

Watanuki

Kikuchi

Toyama

, et al. Mixed connective tissue disease with pulmonary hypertension developing in a chronic myeloid leukemia patient on dasatinib treatment. Rinsho Ketsueki 2018; 59: 174–177.